497845-94-0Relevant academic research and scientific papers
Furoxans (Oxadiazole-4 N-oxides) with Attenuated Reactivity are Neuroprotective, Cross the Blood Brain Barrier, and Improve Passive Avoidance Memory
Horton, Austin,Nash, Kevin,Tackie-Yarboi, Ethel,Kostrevski, Alexander,Novak, Adam,Raghavan, Aparna,Tulsulkar, Jatin,Alhadidi, Qasim,Wamer, Nathan,Langenderfer, Bryn,Royster, Kalee,Ducharme, Maxwell,Hagood, Katelyn,Post, Megan,Shah, Zahoor A.,Schiefer, Isaac T.
, p. 4593 - 4607 (2018)
Nitric oxide (NO) mimetics and other agents capable of enhancing NO/cGMP signaling have demonstrated efficacy as potential therapies for Alzheimer's disease. A group of thiol-dependent NO mimetics known as furoxans may be designed to exhibit attenuated reactivity to provide slow onset NO effects. The present study describes the design, synthesis, and evaluation of a furoxan library resulting in the identification of a prototype furoxan, 5a, which was profiled for use in the central nervous system. Furoxan 5a demonstrated negligible reactivity toward generic cellular thiols under physiological conditions. Nonetheless, cGMP-dependent neuroprotection was observed, and 5a (20 mg/kg) reversed cholinergic memory deficits in a mouse model of passive avoidance fear memory. Importantly, 5a can be prepared as a pharmaceutically acceptable salt and is observed in the brain 12 h after oral administration, suggesting potential for daily dosing and excellent metabolic stability. Continued investigation into furoxans as attenuated NO mimetics for the CNS is warranted.
FUROXANS AS THERAPIES FOR NEURODEGENERATIVE DISORDERS
-
Paragraph 00170; 00182, (2018/06/06)
Furoxan compounds, compositions comprising the same, and methods of making and using the same, are described.
Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives
Tosco, Paolo,Bertinaria, Massimo,Di Stilo, Antonella,Cena, Clara,Sorba, Giovanni,Fruttero, Roberta,Gasco, Alberto
, p. 4750 - 4759 (2007/10/03)
Synthesis and pharmacological characterisation of a series of compounds in which the oxime substructure present in imoproxifan was constrained in the pentatomic NO-donor furoxan ring, as well as their structurally related furazan analogues devoid of NO-do
